| Structural highlights
Disease
PI4KA_HUMAN Combined immunodeficiency-enteropathy spectrum;Autosomal recessive spastic paraplegia type 84;Bilateral perisylvian polymicrogyria. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry.
Function
PI4KA_HUMAN Acts on phosphatidylinositol (PtdIns) in the first committed step in the production of the second messenger inositol-1,4,5,-trisphosphate.[1] [2]
Publication Abstract from PubMed
Phosphatidylinositol 4 kinase IIIalpha (PI4KIIIalpha/PI4KA) is an essential lipid kinase that plays a critical role in regulating plasma membrane identity. PI4KA is primarily recruited to the plasma membrane through the targeted recruitment by the proteins, EFR3A and EFR3B, which bind to the PI4KA accessory proteins TTC7 (TTC7A/B) and FAM126 (FAM126A/B). Here we characterised how both EFR3 isoforms interact with all possible TTC7-FAM126 combinations and developed a nanobody that specifically blocked EFR3-mediated PI4KA recruitment in TTC7B containing complexes. Most EFR3-TTC7-FAM126 combinations show similar binding affinities, with the exception of EFR3A-TTC7B-FAM126A, which binds with a approximately 10-fold higher affinity. Moreover, we showed that EFR3B phosphorylation markedly decreased binding to TTC7-FAM126. Using a yeast display approach, we isolated a TTC7B selective nanobody that blocked EFR3 binding. Cryo-electron microscopy and hydrogen deuterium exchange mass spectrometry showed an extended interface with both PI4KA and TTC7B that sterically blocks EFR3 binding. The nanobody caused decreased membrane recruitment both on lipid bilayers and in cells, with decreased PM production of PI4P. Collectively, these findings provide new insights into PI4KA regulation and provide a tool for manipulating PI4KA complexes, that may be valuable for therapeutic targeting.
Development of an inhibitory TTC7B selective nanobody that blocks EFR3 recruitment of PI4KA.,Suresh S, Shaw AL, Akintola DK, Lunke M, Doerr S, Rohilla P, Balla T, Yip CK, Hansen SD, Cobb JA, Burke JE J Biol Chem. 2025 Nov 4:110886. doi: 10.1016/j.jbc.2025.110886. PMID:41197736[3]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Gehrmann T, Gülkan H, Suer S, Herberg FW, Balla A, Vereb G, Mayr GW, Heilmeyer LM Jr. Functional expression and characterisation of a new human phosphatidylinositol 4-kinase PI4K230. Biochim Biophys Acta. 1999 Mar 25;1437(3):341-56. PMID:10101268 doi:10.1016/s1388-1981(99)00029-3
- ↑ Nakatsu F, Baskin JM, Chung J, Tanner LB, Shui G, Lee SY, Pirruccello M, Hao M, Ingolia NT, Wenk MR, De Camilli P. PtdIns4P synthesis by PI4KIIIα at the plasma membrane and its impact on plasma membrane identity. J Cell Biol. 2012 Dec 10;199(6):1003-16. PMID:23229899 doi:10.1083/jcb.201206095
- ↑ Suresh S, Shaw AL, Akintola DK, Lunke M, Doerr S, Rohilla P, Balla T, Yip CK, Hansen SD, Cobb JA, Burke JE. Development of an inhibitory TTC7B selective nanobody that blocks EFR3 recruitment of PI4KA. J Biol Chem. 2025 Nov 4:110886. PMID:41197736 doi:10.1016/j.jbc.2025.110886
|
